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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
We will examine the effects of pharmacy-based management interventions compared to an active control, treatment as usual or no
intervention/ waiting list, at improving depression outcomes in adults.
B A C K G R O U N D
Some services provided by pharmacists may have positive effects
on patient health, including improvedmanagement of blood pres-
sure and physical function (de Barra 2018). Antidepressant man-
agement for depression is usually achieved through general practi-
tioner (GP) contact andmonitoring,which typically involves regu-
lar appointments (e.g. every two to four weekswithin the first three
months) in order to assess response and tolerance to treatment
(NICE 2018). Community pharmacists may be well placed to
have a role in antidepressant management because of their unique
pharmacotherapeutic knowledge and ease of access for patients. In
the UK, there have been efforts to raise public awareness about the
role that pharmacists can play as part of multidisciplinary team
to better support people with managing their health conditions,
including mental health problems (Royal Pharmaceutical Society
2018).
In England, an estimated 89.2% of the population have access to
a community pharmacy within a 20-minute walk; in the most de-
prived areas, this figure increases to 99.8%of the population (Todd
2014). Therefore, pharmacy teams - working in community, gen-
eral practice or secondary care - are ideally placed to offer proac-
tive interventions to people with depression or depressive symp-
toms. A narrative evidence synthesis by Rubio-Valera 2014 sug-
gests that pharmacists, specifically, have skills in medication man-
agement, provision of drug information, supporting and advising
patients about their medicines and facilitating medication adher-
ence strategies in mental health care. Although pharmacy-based
management interventions can vary in their components, there is
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scope for these approaches to be used in partnership with other
healthcare professionals (for example, as part of a collaborative
care approach). Previous research has suggested that multi-profes-
sional approaches (involving more than one type of health profes-
sional, using a structuredmanagement plan and scheduled follow-
ups, with enhanced inter-professional communication) have the
potential to improve the management of depression in primary
care settings (Archer 2012; Gilbody 2003; Gunn 2006). However,
despite this potential, and the emerging evidence of the role of
pharmacy-basedmanagement interventions for depression, the ef-
fectiveness and acceptability of these interventions is not yet well
understood.
Description of the condition
Depression can be characterised by low mood; markedly dimin-
ished interest or pleasure in activities; impaired cognitive function;
fatigue or reduced or disturbed sleep; feelings of worthlessness;
and significant decrease or increased appetite (APA 2013; Otte
2016). The aetiology and maintenance of depression is complex
and multifactorial, involving environmental and social factors, as
well as genetic and biological factors affecting function changes
and regions of the brain (Otte 2016). The condition can be re-
current or long-term and chronic, and often results in debilitat-
ing burden that can interfere with family, home, social and work
responsibilities (Marquez 2016).
Depression is a common mental health problem, with more than
300 million people globally estimated to be living with the condi-
tion (WHO 2018). It is the leading cause of disability worldwide
and a major contributor to the overall burden of disease (WHO
2018). In extensive global population research on Global Burden
of Disease involving 188 countries between 1990 and 2013, de-
pression was found to be one of the top 10 causes of years lived
with disability in every country studied, with higher rates of de-
pression typically found in women (Vos 2015). The global point
prevalence of depression is reported to be 3.2% for men and 5.5%
for women (Ferrari 2013a; Ferrari 2013b; Whiteford 2013). It is
estimated that annually 12 billion days of lost productivity (equiv-
alent to 50 million years of work) are attributable to depressive
and anxiety disorders (which are often comorbid with each other)
combined, with an estimated cost of USD 925 billion, a cost that
is anticipated to grow in coming years (Chisholme 2016).
Antidepressants have long been a mainstay of pharmacological
treatment for depression (Taylor 2015), and have been reported
to be more effective than placebo (Cipriani 2018). However, it
is common for patients not to take antidepressant medication as
prescribed, with around 50% of patients likely to prematurely
discontinue taking their medication after six months. Premature
discontinuation of antidepressant therapy has been linked to in-
creased healthcare costs, poor treatment outcomes, and increased
risk of relapse and recurrence (Chong 2011).
Medication non-compliance can be broken down into the con-
cepts of ’adherence’ and ’persistence’; the former defined as “the
extent to which a patient acts in accordance with the prescribed
interval, and dose of a dosing regimen”, and the latter “the dura-
tion of time from initiation to discontinuation of therapy”, which
can be related to the effects of the medication itself, including
any adverse effects (Cramer 2008). Non-compliance can impact
on the potential for antidepressant medication to improve symp-
toms of depression and may be related to specific concerns (such
as experience of adverse effects, fear of addiction, lack of belief
in the role of medication in helping to treat depression) as well
as factors associated with medication management (such as in-
sufficient provision of patient information/education, poor post-
prescription follow-up, or other less explicit reasons) (Anderson
2013; Martin-Vazquez 2016; Sansone 2012).
Description of the intervention
Pharmacy-based management interventions can be delivered by a
single pharmacist or the wider pharmacy support team. In the con-
text of depression, pharmacy-based management interventions are
often delivered in partnership with other healthcare professionals
- usually as part of a collaborative care approach - focusing on
improving patient adherence and persistence with antidepressant
medication. This can be done in several ways: firstly, by providing
patient support, counselling, and education; secondly, by moni-
toring or following up adverse effects of medications; and, thirdly,
under specific protocols, titrating doses of medications according
to patient response (Brook 2005; Capoccia 2004; Finley 2003).
These interventions can be provided face-to-face, using written
support materials or visual information relating to medication,
through telephone support, or viamore formal ’counselling’ strate-
gies (Adler 2004; Al-Saffar 2005), and they may happen alongside
the involvement of care managers, mental health specialists, and
primary care physicians (Aljumah 2015; Rickles 2005).
As the intervention can be delivered in multiple ways and, given
the number of interacting components involved (including the
number and difficulty of behaviours required by those delivering
or receiving the intervention, the number and potential variability
of outcomes, and the degree of flexibility or tailoring of the inter-
vention permitted) it can be described as a complex intervention
(Petticrew 2011).
How the intervention might work
Working alone or as part of a wider collaborative care approach, a
goal of pharmacy-based management is to improve patient adher-
ence and persistence rates with antidepressant medication. A key
aspect of effective collaborative care is ’casemanagement’ (Gilbody
2003), which has been described as a ’health worker taking re-
sponsibility for proactively following up patients, assessing patient
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adherence to psychological and pharmacological treatments,mon-
itoring patient progress, taking action when treatment is unsuc-
cessful, and delivering psychological support’ (Von Korff 2001).
In addition to improving patient adherence and persistence, phar-
macy-based management interventions might also involve the de-
livery of direct psychological interventions to patients with de-
pression. An example of this is behavioural activation (BA) ther-
apy, which uses principles of operant conditioning by encourag-
ing people with depression to reconnect with environmental pos-
itive reinforcement (Ekers 2014). Behavioural activation can be
effective when delivered by paraprofessionals (Gilbody 2017), and
current research is exploring if it can be delivered by community
pharmacies to people with long-termphysical health problems and
subthreshold depression (ISRCTN11290592).
Qualitative work has shown that people tend to form different
relationships with a pharmacist compared to other healthcare pro-
fessionals, such as primary care practitioners or general practi-
tioners (GPs), indicating that people might be more likely to see
a pharmacist to discuss certain aspects of their health (Lindsey
2016). Previous research has demonstrated how pharmacist-based
management interventions, including providing patient support,
counselling or coaching patients about their medication and what
to expect, can improve antidepressant adherence rates (Al-Saffar
2005; Brook 2005). It is proposed that pharmacy-based manage-
ment interventions, such as engaging patients through face-to-face
or remote counselling, education and advice (e.g. via teleconfer-
encing, or ’take-home’ audio/visual materials) alongside prescrib-
ing and monitoring of antidepressant medication, can also im-
prove depressive symptoms.
Why it is important to do this review
Pharmacists are now engaging with patients in different ways, and
it is important to bring together the randomised evidence for phar-
macy-based approaches for depression to determine effectiveness
not only on adherence levels, depressive symptoms and adverse
effects of prescribed medication, but also on broader patient-cen-
tred outcomes including acceptability, quality of life and levels
of social functioning. Research involving community household
surveys from 21 countries showed that only a minority of peo-
ple received ’minimally adequate treatment’ for depression. This
finding equates to 1 in 5 people in high-income countries, and
1 in 27 in low-/lower-middle-income countries, highlighting the
need to implement fundamental transformations involving com-
munity education and outreach, beyond that currently being of-
fered in primary and secondary care services (Thornicroft 2017).
Treatment and support for depression clearly extends beyond the
pharmacological; however, due to inadequate resources, antide-
pressants are more often used than treatment alternatives, for ex-
ample, psychological therapies (Cipriani 2018).
Against this backdrop, there are emerging policy expectations for
pharmacies to expand their professional responsibilities beyond
retail and dispensing to encompass more patient-centred services,
including counselling and support, education, monitoring adverse
events, and advice relating to prescribedmedication andmedicines
optimisation and titration, resulting in a trend for community
pharmacy medicine management interventions being introduced
globally (including in Australia, Canada, New Zealand, Switzer-
land, the United States and England) (Latif 2018). Even with a
stronger push for pharmacy-based interventions, there remains
ambivalence amongst pharmacists as towhether the public arewill-
ing to engage or would readily accept advice and support (Eades
2011; Rodgers 2016).
Pharmacy-basedmanagement strategies have shown some promis-
ing effects in other areas of healthcare (de Barra 2018). Whilst
existing systematic reviews in this area have examined the effects
on improving patient adherence to antidepressants in general, for
adherence to be clinically important, improvements in symptoms
of depression and other person-centred outcomes are essential.
More evidence is needed on broader, patient-important outcomes,
including depressive symptoms, acceptability of the intervention,
healthcare utilisation and quality of life (Hanlon 2004; Holland
2008; Nkansah 2010; Readdean 2018; Royal 2006; Rubio-Valera
2013; Yaghoubi 2017). The degree to which a pharmacy-based
management approach might be beneficial, acceptable to patients,
effective and cost-effective as part of the overall management for
those with depression is, to date, unclear. A systematic review of
randomised controlled trials will help answer these questions and
add important knowledge to the currently sparse evidence base.
O B J E C T I V E S
We will examine the effects of pharmacy-based management in-
terventions compared to an active control, treatment as usual or
no intervention/ waiting list, at improving depression outcomes
in adults.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include all randomised controlled trials (RCTs) and clus-
ter-RCTs where a pharmacy-based intervention is compared to
treatment as usual, waiting list or an alternative intervention in
the management of depression. The intervention may be deliv-
ered within the pharmacy or external to the pharmacy (e.g. in a
hospital, clinic, online, etc.) and/or in the community, provided
that the pharmacist/wider pharmacy team is involved.
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Types of participants
We will include all adults (defined as 16 years or over with no
upper age limit), with a primary diagnosis of depression according
to an international diagnostic classification, including for exam-
ple, the Diagnostic and Statistical Manual of Mental Disorders
(APA 2013) or the International Classification of Diseases (ICD)
(WHO 1992), as well as depressive symptoms diagnosed via self-
reported scales or questionnaires. We will also include trials that
do not report how depression is diagnosed or classified, but we
will perform a sensitivity analysis to look at their impact on the
overall estimate of effect. Participants will have been prescribed
an antidepressant (including but not limited to: selective sero-
tonin reuptake inhibitors; serotonin norepinephrine reuptake in-
hibitors; tricyclic antidepressants; monoamine oxidase inhibitors;
tetracyclic antidepressants; noradrenergic and specific serotonergic
antidepressants) by their primary care physician for the treatment
of their diagnosed depression or depressive symptoms. Should we
identify studies that include a mixed age population (for example,
including participants under the age of 16) we will attempt to
obtain results from participants aged 16 years or above. If this is
not possible, we will exclude the study.
We have included adults as defined as 16 years and over.Whilst we
expect most studies to use a cut of point of 18 and above, we note
that people aged 16 plus can consent to take part in research. We
judge those studies would be relevant to this review if identified
and as such will use the lower threshold.
Comorbidities
We will also include people with any kind of physical (e.g. long-
term conditions, diabetes) or mental health comorbidity (e.g. anx-
iety), provided that the management of depression is the primary
focus of the study.
Types of interventions
Experimental intervention
Where permissible, we will label interventions in meta-analysis
using the following criteria.
1. Delivery of the pharmacy-based management intervention
These will be grouped according to the profession(s)
responsible for delivering the intervention as follows:
1.1 Pharmacist only
1.2 Pharmacist plus the wider pharmacist team
1.3 Multidisciplinary care group (involving the pharmacist
+/- the wider care team, and other members of the healthcare
team)
2. Types of comparator intervention or control
2.1 Active control (e.g. other non-pharmacy-based
management, or psychological intervention)
2.2 Treatment as usual (i.e. standard pharmacy interaction)
2.3 No intervention/waiting list
Two review authors will independently assess and classify the phar-
macy-based management intervention and comparator interven-
tion/control. In the case of disagreement, consensuswill be reached
through discussion with a third review author.
Types of outcome measures
Where included studies use more than one tool for the same out-
come measure (e.g. depression symptom severity), we will include
the measure defined by the individual study as the primary out-
come.
Primary outcomes
1. Depression symptom level
Asmeasuredusing validated patient-reported depressionmeasures,
such as the Beck Depression Inventory (BDI; Beck 1961), or the
Patient Health Questionnaire-9 (PHQ-9; Kroenke 2001).
2. Acceptability of intervention
Based on the number of people discontinuing the intervention by
leaving the study early.
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Secondary outcomes
1. Diagnosis of depression
As measured using validated clinician-rated depression measures,
such as the Hamilton Rating Scale for Depression (HAM-D;
Hamilton 1960).
2. Non-adherence to medication
The number of participants not taking antidepressant medication
as prescribed, assessed via self-report, through healthcare records/
clinician-reported adherence scales, such as the Morisky Medi-
cation Adherence Scale (MMAS; Krousel-Wood 2009; Morisky
1986; Morisky 2008).
3. Frequency of primary care appointments (e.g. GP)
Based on any data relating to primary care service use as reported
in the trial.
4. Quality of life
As assessed using any validated quality of life measure, such as the
World Health Organization Quality of Life Assessment (WHO-
QOL; WHO 1998) or the Short Form (SF-36; Ware 1993).
5. Social functioning
As assessed using any validated social functioning measure, such
as the Global Assessment of Functioning scale (GAF; APA 2000),
or the Social Functioning Questionnaire (SFQ; Tyrer 2005).
6. Any adverse event
As reported in the trial.
Timing of outcome assessments
We will sub-group time outcomes as follows:
• intervention endpoint;
• 6-12 months from intervention endpoint (’Medium-term’);
and
• 12 months or more from intervention endpoint (’Longer-
term’).
Search methods for identification of studies
Cochrane Common Mental Disorders Controlled
Trials Register (CCMD-CTR)
Cochrane Common Mental Disorders maintains a specialised
register of RCTs, the CCMD-CTR. This register contains over
40,000 reference records (reports of RCTs) for anxiety disorders,
depression, bipolar disorder, eating disorders, self-harm and other
mental disorders within the scope of this Group. The CCMD-
CTR is a partially studies-based register with more than 50% of
reference records tagged to around 12,500 individually PICO-
coded study records. Reports of trials for inclusion in the reg-
ister are collated from (weekly) generic searches of MEDLINE
(1950 onwards), Embase (1974 onwards) and PsycINFO (1967
onwards), quarterly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL) and review-specific searches of ad-
ditional databases. Reports of trials are also sourced from interna-
tional trial registries, drug companies, the handsearching of key
journals, conference proceedings and other (non-Cochrane) sys-
tematic reviews andmeta-analyses. Details of CCMD’s core search
strategies (used to identify RCTs) can be found on the Cochrane
Common Mental Disorders website, with an example of the core
MEDLINE search displayed in Appendix 1.
The CCMD-CTR is current to June 2016.
Electronic searches
Searches will be developed and conducted by Information Spe-
cialist (RS) in collaboration with CCMD’s Information Special-
ist (SD) (see Appendix 2 for details of the original search run in
2014).
1. Cochrane Specialised Register (CCMD-CTR)
The Information Specialist with Cochrane Common Mental Dis-
orders (SD) will search the Specialised Register (CCMD-CTR-
Studies andCCMD-CTR-References) (all years to June 2016), us-
ing the following terms (for setting/healthcare professional (only):
pharmacy or pharmacies or pharmacist* [all fields].
2. Additional bibliographic database searches
The Information Specialists will share searches of the following
bibliographic databases, using relevant subject headings, keywords
and search syntax appropriate to each resource (Appendix 3).
• Ovid MEDLINE (1946 onwards).
• The Cochrane Library Central Register of Controlled Trials
(CENTAL) (current issue).
• Ovid PsycINFO (1806 onwards).
• Ovid Embase (1974 onwards).
We will not apply any restriction on date, language or publication
status to the searches.
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3. International Trial Registries
We will search ClinicalTrials.gov (clinicaltrials.gov), and the
WHO International Clinical Trials Registry Platform ( ICTRP) (
www.who.int/ictrp/en) to identify ongoing or unpublished stud-
ies.
Three review authors (SJS, NW and AT) will independently con-
sider all abstracts retrieved from the search results for relevancy,
and screen full text reports to identify studies for inclusion in the
review using Covidence software (Covidence 2018). Any disagree-
ment will be managed through discussion and referred to a third
review author (LW). If agreement cannot be reached, the study
will be excluded from the review.
Searching other resources
1. Theses
We will search the following databases to identify relevant PhD
theses (all available years).
• DART-Europe E-theses Portal ( www.dart-europe.eu).
• EThOS - the British Libraries e-theses online service (
ethos.bl.uk).
• Open Acces Theses and Dissertations ( oatd.org).
• ProQuest Dissertations and theses database (c/o
dissexpress.umi.com).
2. Reference lists
The Information Specialist with Cochrane Common Mental Dis-
orders (CCMD) will perform a search for systematic reviews and
meta-analyses on the Cochrane Database of Systematic Reviews
(CDSR) (current issue); Database of Reviews of Effects (DARE),
Health Technology Assessments database (HTA), Ovid MED-
LINE (1946 onwards); Embase (1974 onwards) and PsycINFO
(1806 onwards). We will check the reference list of all relevant re-
views retrieved from this search together with reports of included
studies to help identify additional research relevant to the review.
3. Personal communication
Wewill contact principal investigators of relevant studies to ensure
we have included all relevant published or unpublished research
and to request additional data where necessary.
Prior to publication we will search for retractions or errata of all
included studies. We will also ensure the search date is within 12
months of publication.
Data collection and analysis
We will use the systematic review management software, Covi-
dence (Covidence 2018), for managing citations, screening titles
and abstracts, uploading references, screening full texts, data ex-
traction, and assessing risk of bias. We will then use Review Man-
ager 5 software for data synthesis and analysis (Review Manager
2014).
Selection of studies
In the first stage, review authors (RS, SJS, NW and AT) will in-
dependently screen titles and abstracts from the results of the lit-
erature searches, including potential trials relevant to the review
and excluding others based on the prespecified criteria. If any dis-
agreements arise, this will be discussed with a fourth review author
(LW). In the second stage, the same review authors (RS, SJS, NW
and AT) will collate all potentially relevant full records and per-
form a second screening, inspecting the full-texts, selecting studies
that will be included in the review, excluding studies that are not
relevant andproviding reasons for our decision. Any disagreements
that arise will be resolved by discussion with the fourth review
author (LW). Where it is not possible to reach an agreement on
the inclusion or exclusion of a study, we will add that study to the
list of those ’awaiting assessment’ and contact the trial authors to
request further information relating to the trial in order to make
a decision.
We will document and present the study search process and sub-
sequent exclusion and inclusion decisions using a PRISMA study
flow diagram, and we will also produce narrative text summarising
identified studies.
Data extraction and management
We will qualitatively extract methodological, participant, inter-
vention and outcome characteristics of included studies ( includ-
ing author details; country of study; study design; description of
study setting; recruitment process; description of participants; de-
scription of intervention; primary and secondary outcomes at all
assessments; as well as funding and potential conflicts of interest of
study authors). Data will then be extracted from each trial for pre-
specified outcomes at endpoint; this will be done independently
by four review authors ( SJS, LW,NWandAT) using theCochrane
Consumer and Communicaton Group’s standardised data extrac-
tion tool ( cccrg.cochrane.org/author-resources). Findings will be
compared and any differences referred back to the original text.
If agreement cannot be reached, the outstanding issue will be dis-
cussed with a fourth review author (DE).
Assessment of risk of bias in included studies
We will rate risk of bias according to Cochrane’s ’Risk of bias’ tool
(Higgins 2011a). The six domains of which include:
1. random sequence generation;
2. allocation concealment;
3. blinding of outcome assessment;
4. incomplete outcome data;
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5. selective reporting;
6. other sources of bias (e.g. funding, affiliations and
declarations of interest of study authors).
Three authors (SJSNWandAT)will independently perform ’Risk
of bias’ assessments across individual studies, rating domains as
either a ’low’, ’unclear’, or ’high’ risk of bias. We will accompany
our assessment with a supporting quotation from the study report,
including quotes and page numbers in the risk of bias tables. We
will also summarise the ’Risk of bias’ judgements across different
studies for each of the domains listed above. Any disagreement
will be resolved by discussion with either authors DE or LW.
Measures of treatment effect
We will input all data into Review Manager 5 software (Review
Manager 2014). For dichotomous outcomes, we will calculate the
risk ratio (RR) and where overall risks are statistically significant
(P = 0.05) we plan to calculate the number needed to treat for
an additional beneficial outcome (NNTB) using the risk differ-
ence (RD). For continuous data we will use standardised mean
differences (SMDs), where different standardised scales are used
to measure the same outcome, and the mean difference (MD)
when the same scale is used, or only one study is included in the
meta-analysis. We will consider SMD effect sizes of 2 as small, 5
as medium, and 8 and above as large (Cohen 1988; Pace 2011).
Unit of analysis issues
Cluster-randomised trials
Should we identify any cluster-RCTs, we plan to incorporate re-
sults into the review, ensuring that data were analysed within the
individual study with consideration of their clustering. As per the
guidance of the Cochrane Handbook for Systematic Reviews of In-
terventions, we will report data where proper adjustment for the
intracluster correlation coefficient (ICC) had been undertaken
(Higgins 2011c). If the ICC is not provided, we will contact in-
dividual study authors to request them.
Many of these studies, however, are incorrectly analysed as though
the unit of allocation had been the individual participants, as op-
posed to a group (or ’cluster’) of participants. This is often referred
to as a ‘unit of analysis error’ because the unit of analysis is dif-
ferent from the unit of allocation. If this is the situation, we will
approximately correct analyses if the following information can be
extracted:
• the number of clusters (or groups) randomised to each
intervention group; or the average (mean) size of each cluster;
• the outcome data ignoring the cluster design for the total
number of individuals (for example, number or proportion of
individuals with events, or means and standard deviations); and
• an estimate of the ICC (Higgins 2011c).
Trials with multiple treatment arms
Where trials have additional arms that do not include a pharmacy-
based intervention, wewill only include data relating to pharmacy-
based interventions and control arms. We will include data from
other treatment arms provided the interventions are relevant to our
inclusion criteria. If we include data frommultiple treatment arms,
we will combine groups to create a single pair-wise comparison
(Higgins 2011c). If there were two potential control groups, we
would present them in separate comparisons (either: an active
control, treatment as usual, or no intervention/waiting list - see
Types of interventions). If however, the control arms displayed
marked similarities (e.g. two types of active controls that did not
involve a pharmacy-based management intervention) then we will
combine the results of these and present them in one comparison,
e.g. ‘Pharmacy-based management versus active control’.
Dealing with missing data
When reported, wewill extract data where appropriate imputation
methods (e.g. multiple imputation, simple imputation methods
with adjustment to the standard error etc.) or statistical models al-
lowing for missing data have been used. However, where such data
is not available we will extract observed case data. Where a com-
bination of imputed and observed case data are available we will
meta-analyse these using the generic inverse variance method and
investigate the impact of excluding imputed data in a Sensitivity
analysis.
If data are missing, we will contact the trial authors to request fur-
ther information and document their responses. For dichotomous
outcomes, we will use intention-to-treat (ITT) analysis where this
is reported, and mention in the ’Risk of bias’ table whether or
not ITT analysis was done. We will assume that dropouts from
treatment are treatment failures unless trialists expressly state oth-
erwise.
For continuous data, we will contact trial authors for any missing
statistics or calculate them using available reported data. For ex-
ample, we will calculate the SDs from the standard error (SE) or P
values (Altman 1996), or from confidence interval (CI), T values,
or P values, as described the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011b).
Assessment of heterogeneity
Statistical heterogeneity will be examined using the I2 statistic
for statistical variation across studies (Deeks 2011). The I2 statis-
tic provides a measure of the proportion of dispersion of effects
across studies that reflect real differences rather than random er-
ror. Benchmark values of 0% to 40% might not be important,
30% to 60% may represent moderate heterogeneity, 50% to 90%
may represent substantial heterogeneity, and 75% to 100% would
represent considerable heterogeneity, and we will report with 95%
CIs. When we detect substantial levels of statistical heterogeneity
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(via visual inspection of graphs, and the presence of an I2 greater
than or equal to 75%, accompanied by a statistically significant
Chi2), we will closely inspect data to ensure they have been in-
putted correctly. When making this inspection, to avoid impos-
ing arbitrary thresholds, we will take into account (i) the mag-
nitude and direction of the observed effect, and (ii) the strength
of the evidence for heterogeneity (for example, the P value from
Chi2 test, or CI from the I2 test). We will also judge clinical and
methodological heterogeneity between included trials by inspect-
ing for any outlying people, situations or methods which we did
not expect would arise. We will document and discuss these fac-
tors (see Subgroup analysis and investigation of heterogeneity and
Sensitivity analysis).
Assessment of reporting biases
Should meta-analysis include more than 10 trials, we will use a
funnel plot to help detect instances of reporting biases, where a
symmetrical funnel plot is likely to indicate low publication bias
while an asymmetric funnel plot may indicate likely publication
bias in included trials (Sterne 2011).
Data synthesis
Previous systematic reviews have highlighted wide variation in
pharmacist-based interventions and reported outcomes, and have
noted high levels of heterogeneity in their data (de Barra 2018; Bell
2005; Bower 2006).We will therefore use a random-effects model
for our analyses, taking account of both within- and between-
study variance and following the assumption that different studies
are estimating different, yet related, intervention effects (Deeks
2011). We will test heterogeneity using both the Chi² test and
the I² statistic (as outlined above). In cases of doubt, we will seek
expert advice regarding combining treatment groups to ensure that
findings are clinically meaningful. If ameta-analysis is not possible
(e.g. due to insufficient data or high heterogeneity), we plan to
provide a narrative synthesis of the evidence (Noyes 2011).
Subgroup analysis and investigation of heterogeneity
We plan to conduct the following subgroup analysis in order to
reduce the likelihood of spurious findings on factors that may
influence heterogeneity. Such factors include whether participants
have additional mental and/or physical health comorbidities, as
well as their baseline severity of depression. In addition, delivery
method of the pharmacy-based intervention can be varied, for this
reason we plan to utilise subgroups for when the intervention is
delivered in-person or remotely (i.e. without in-person contact
with the pharmacy/ multidisciplinary team). In order to limit the
number of subgroups, and to prevent knowledge of trial results
from dictating which subgroups should be analysed, we anticipate
the following subgroups:
1. Participant characteristics
1.1 Patients with physical and mental health comorbidities
Subgrouping trials according to whether or not they provided data
for participants either with no comorbidities, or with physical and/
or mental health comorbidities.
1.2 Baseline severity of depression
As defined as mild, moderate or severe in individual studies, or
using cut-points for validated rating scales, such as the Patient
Health Questionnaire 9 (PHQ-9; Kroenke 2001), or the Beck
Depression Inventory, second edition (BDI-II; Beck 1996).
2. Intervention characteristics: delivery method
2.1 In-person
Likely subgroups to include, for example, one-to-one/individual;
group support; home/clinic visits.
2.2 Remote
Likely subgroups to include, for example, telephone; digital tech-
based including email or app-based; other written communica-
tion.
Sensitivity analysis
We plan to conduct a sensitivity analysis for primary outcomes for
the following reasons.
1. Risk of bias
If an included trial is rated as a high risk of bias on two or more of
the risk of bias domains, we will remove this trial to see whether
removal would make a substantive difference to the results.
2. Assumptions for missing data
Wheremeta-analyses include data from a combination of imputed
and completer data we will conduct sensitivity analyses excluding
imputed data. We will compare these estimates with the main
analyses to assess any important differences.
3. Classification of depression
Where a trial does not report how depression is classified, we will
remove this trial to see whether removal would make a substantive
difference to the results.
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’Summary of findings’ table
We plan to construct a ’Summary of findings’ table using the
GRADE approach to assess the extent to which there may be con-
fidence that the observed effect estimate reflects the true underly-
ing effect (Guyatt 1998). The approach will also allow us to make
a judgement on the quality of the available evidence. We choose
the following outcomes at intervention endpoint as the most im-
portant.
1. Depression symptom level (patient-reported)
2. Acceptability of intervention
3. Diagnosis of depression (clinician-rated)
4. Non-adherence to medication
5. Frequency of primary care appointments (e.g. GP)
6. Quality of life
7. Social functioning
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A P P E N D I C E S
Appendix 1. Specialised Register: CCMD’s core MEDLINE search strategy
The search strategy listed below is the weekly OVID MEDLINE search used to inform Cochrane Common Mental Disorders
specialised register. It is based on a list of terms for all conditions within the scope of Cochrane Common Mental Disorders
plus a sensitive RCT filter
1. [MeSH Headings]:
eating disorders/ or anorexia nervosa/ or binge-eating disorder/ or bulimia nervosa/ or female athlete triad syndrome/ or pica/ or
hyperphagia/ or bulimia/ or self-injurious behavior/ or self mutilation/ or suicide/ or suicidal ideation/ or suicide, attempted/ or
mood disorders/ or affective disorders, psychotic/ or bipolar disorder/ or cyclothymic disorder/ or depressive disorder/ or depression,
postpartum/ or depressive disorder, major/ or depressive disorder, treatment-resistant/ or dysthymic disorder/ or seasonal affective
disorder/ or neurotic disorders/ or depression/ or adjustment disorders/ or exp antidepressive agents/ or anxiety disorders/ or agoraphobia/
or neurocirculatory asthenia/ or obsessive-compulsive disorder/ or obsessive hoarding/ or panic disorder/ or phobic disorders/ or stress
disorders, traumatic/ or combat disorders/ or stress disorders, post-traumatic/ or stress disorders, traumatic, acute/ or anxiety/ or anxiety,
castration/ or koro/ or anxiety, separation/ or panic/ or exp anti-anxiety agents/ or somatoform disorders/ or body dysmorphic disorders/
or conversion disorder/ or hypochondriasis/ or neurasthenia/ or hysteria/ ormunchausen syndrome by proxy/ ormunchausen syndrome/
or fatigue syndrome, chronic/ or obsessive behavior/ or compulsive behavior/ or behavior, addictive/ or impulse control disorders/
or firesetting behavior/ or gambling/ or trichotillomania/ or stress, psychological/ or burnout, professional/ or sexual dysfunctions,
psychological/ or vaginismus/ or Anhedonia/ or Affective Symptoms/ or *Mental Disorders/
2. [Title/ Author Keywords]:
(eating disorder* or anorexia nervosa or bulimi* or binge eat* or (self adj (injur* or mutilat*)) or suicide* or suicidal or parasuicid* or
mood disorder* or affective disorder* or bipolar i or bipolar ii or (bipolar and (affective or disorder*)) or mania or manic or cyclothymic*
or depression or depressive or dysthymi* or neurotic or neurosis or adjustment disorder* or antidepress* or anxiety disorder* or
agoraphobia or obsess* or compulsi* or panic or phobi* or ptsd or posttrauma* or post trauma* or combat or somatoform or somati#
ation or medical* unexplained or body dysmorphi* or conversion disorder or hypochondria* or neurastheni* or hysteria or munchausen
or chronic fatigue* or gambling or trichotillomania or vaginismus or anhedoni* or affective symptoms or mental disorder* or mental
health).ti,kf.
3. [RCT filter]:
(controlled clinical trial.pt. or randomised controlled trial.pt. or (randomi#ed or randomi#ation).ab,ti. or randomly.ab. or (random*
adj3 (administ* or allocat* or assign* or class* or control* or determine* or divide* or distribut* or expose* or fashion or number* or
place* or recruit* or subsitut* or treat*)).ab. or placebo*.ab,ti. or drug therapy.fs. or trial.ab,ti. or groups.ab. or (control* adj3 (trial* or
study or studies)).ab,ti. or ((singl* or doubl* or tripl* or trebl*) adj3 (blind* or mask* or dummy*)).mp. or clinical trial, phase ii/ or
clinical trial, phase iii/ or clinical trial, phase iv/ or randomised controlled trial/ or pragmatic clinical trial/ or (quasi adj (experimental
or random*)).ti,ab. or ((waitlist* or wait* list* or treatment as usual or TAU) adj3 (control or group)).ab.)
4. (1 and 2 and 3)
Records are screened for reports of RCTs within the scope of the Cochrane Common Mental Disorders Group. Secondary reports of
RCTs are tagged to the appropriate study record.
Appendix 2. Previous scoping searches (2014)
In 2014, extensive searches were undertaken by RS and LW to identify any existing or on going studies of pharmacy-based management
for depression in adults (See PROSPERO ref CRD42014013517). We identified studies by searching electronic databases and clinical
trials registries. Databases searched included:
• AMED
• Embase
• CINAHL
• ClinicalTrials.gov
• Cochrane Central Register for Controlled Trials
• Cochrane Database of Systematic Reviews
13Pharmacy-based management for depression in adults (Protocol)
Copyright © 2019 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
• Database of Abstracts of Reviews of Effects (DARE)
• HTA Database
• ISI Web of Science
• ISRCTN registry
• Medline
• PsychArticles
• PsycINFO
We also examined the reference lists of all included studies to identify any additional research relevant to the review question. LW
and RS independently considered whether abstracts of studies retrieved met the inclusion criteria and screened the full text of selected
studies for relevance. Disagreements were resolved by consensus or by referral to a third reviewer (DE).
We identified a total of 851 studies with a focus on depression interventions in community pharmacy settings. Of these, we excluded
734 on the basis of title and/or abstract review, and a further 35 following full text review if they did not meet the inclusion criteria.
There were a total of 60 duplicates, leaving 22 studies for inclusion.
Appendix 3. Review Searches
Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 onwards>
Search Strategy:
--------------------------------------------------------------------------------
[Intervention/Setting]
1 COMMUNITY PHARMACY SERVICES/
2 PHARMACISTS/
3 PHARMACISTS’ AIDES/
4 (pharmacy or pharmacies or pharmacist*).ti,kf,hw.
5 ((pharmacy or pharmacies or pharmacist*) adj3 (advis* or advice or care or healthcare or coach* or commun* or counsel* or
intervention* or model* or program* or service* or support* or treat* or therap* or psychotherap* or prevent*)).ab.
6 (pharmacy or pharmacies or pharmacist*).af.
7 ((collaborat* or coordinat* or co-ordinat* or shared or integrat* or interdisciplinary or inter-disciplinary or stepped) adj3 (care or
healthcare or coach* or counsel* or working or service or model or effort* or intervention* or manage* or program* or treat* or therap*
or psychotherap* or prevent*)).ti,ab,kf.
8 ((treatment or drug* or medicat* or pharmacotherap* or pharmaceutical* or therap* or psychotherap*) adj2 (adher* or comply or
complian* or nonadher* or noncomplian* or collabor$ or commun* or educat* or advis* or advice or direct* or coach* or counsel* or
support* or proactive* or pro-active* or follow-up or collaborat* or coordinat* or co-ordinat* or shared or integrat* or stepped)).ti,ab,kf.
9 (6 and (7 or 8))
10 or/1-5,9
[Population-1]
11 (depress$ or dysthymi$ or mood or affective disorder* or affective symptom*).ti,ab,kf.
12 ((mental* or psychiatr*) adj1 (ill* or disorder* or health or disease or diagnos* or condition)).ti,kf,hw.
13 exp DEPRESSIVE DISORDER/
14 DEPRESSION/
15 or/11-14
[Population-2]
16 exp ANTIDEPRESSIVE AGENTS/
17 exp NEUROTRANSMITTER UPTAKE INHIBITORS/
18 exp MONOAMINE OXIDASE INHIBITORS/
19 PATIENT COMPLIANCE/ or MEDICATION ADHERENCE/
20 (or/16-18) and 19
21 ((adheren* or compliance or nonadheren* or noncompliance or collabor$ or communic* or educat* or advis* or advice or direct* or
counsel* or support* or proactive* or pro-active* or follow-up) adj3 (antidepress* or anti depress* or MAOI* or monoamine oxidase
inhibit* or ((serotonin or norepinephrine or noradrenaline or nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*) adj3
(uptake or reuptake or re-uptake)) or noradrenerg* or antiadrenergic or anti adrenergic or SSRI* or SNRI* or TCA* or psychotropic*
or psychoactive*)).ti,ab,kf.
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22 (20 or 21)
[RCT Filter]
23 controlled clinical trial.pt.
24 randomized controlled trial.pt.
25 (randomi#ed or randomi#ation or randomi#ing).ti,ab,kf.
26 (RCT or “at random” or (random* adj3 (administ* or allocat* or assign* or class* or cluster or control* or determine* or divide* or
division or distribut* or expose* or fashion or number* or place* or pragmatic or quasi or recruit* or split or subsitut* or treat*))).ti,ab,kf.
27 placebo*.ab,ti,kf.
28 trial.ab,ti,kf.
29 (control* and (trial or study or group*) and (placebo or waitlist* or wait* list* or ((treatment or care) adj2 usual))).ti,ab,kf,hw.
30 ((single or double or triple or treble) adj2 (blind* or mask* or dummy)).ti,ab,kf.
31 double-blind method/ or random allocation/ or single-blind method/
32 exp animals/ not humans.sh.
33 (or/23-31) not 32
34 (10 and 15 and 33)
35 (10 and 22 and 33)
36 (34 or 35)
***************************
Cochrane Library (current issue)
#1MeSH descriptor: [Community Pharmacy Services] this term only
#2MeSH descriptor: [Pharmacists] this term only
#3MeSH descriptor: [Pharmacy Technicians] this term only
#4(pharmacy or pharmacies or pharmacist*):ti,kw
#5((pharmacy or pharmacies or pharmacist*) near (advis* or advice or care or healthcare or coach* or commun* or counsel* or
intervention* or model* or program* or service* or support* or treat* or therap* or psychotherap* or prevent*)):ab
#6(pharmacy or pharmacies or pharmacist*):ti,ab,kw
#7((collaborat* or coordinat* or co-ordinat* or shared or integrat* or interdisciplinary or inter-disciplinary or stepped) near (care or
healthcare or coach* or counsel* or working or service or model or effort* or intervention* or manage* or program* or treat* or therap*
or psychotherap* or prevent*)):ab
#8((treatment or drug* or medicat* or pharmacotherap* or pharmaceutical* or therap* or psychotherap*) near/2 (adher* or comply or
complian* or nonadher* or noncomplian* or collabor* or commun* or educat* or advis* or advice or direct* or coach* or counsel* or
support* or proactive* or pro-active* or follow-up or coordinat* or co-ordinat* or shared or integrat* or stepped)):ti,ab,kw
#9#6 AND (#7 OR #8)
#10#1 OR #2 OR #3 OR #4 OR #5 OR #9
#11(depress* or dysthymi* or mood or moods or (affective next disorder*) or (affective next symptom*)):ti,ab,kw
#12((mental* or psychiatr*) NEAR/2 (ill* or disorder* or health or disease or diagnos*)):ti,ab,kw
#13MeSH descriptor: [Depression] this term only
#14MeSH descriptor: [Depressive Disorder] explode all trees
#15#11 OR #12 OR #13 OR #14
#16#10 AND #15
#17MeSH descriptor: [Antidepressive Agents] explode all trees
#18MeSH descriptor: [Neurotransmitter Uptake Inhibitors] explode all trees
#19MeSH descriptor: [Monoamine Oxidase Inhibitors] explode all trees
#20MeSH descriptor: [Patient Compliance] this term only
#21MeSH descriptor: [Medication Adherence] this term only
#22(#17 OR #18 OR #19) AND (#20 OR #21)
#23((adheren* or compliance or nonadheren* or noncompliance or collabor* or communic* or educat* or advis* or advice or direct* or
counsel* or support* or proactive* or pro-active* or follow-up) NEAR (antidepress* or anti depress* or MAOI* or monoamine oxidase
inhibit* or ((serotonin or norepinephrine or noradrenaline or nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*)
NEAR (uptake or reuptake or re-uptake)) or noradrenerg* or antiadrenergic or anti adrenergic or SSRI* or SNRI* or TCA* or
psychotropic*)):ti,ab,kw
#24#22 OR #23
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#25#10 AND #24
#26#16 OR #25
***************************
Ovid PsycINFO <1806 onwards>
Search Strategy:
--------------------------------------------------------------------------------
1 pharmacy/ or pharmacists/
2 (pharmacy or pharmacies or pharmacist*).ti,id.
3 ((pharmacy or pharmacies or pharmacist*) adj3 (advis* or advice or care or healthcare or coach* or commun* or counsel* or
intervention* or model* or program* or service* or support* or treat* or therap* or psychotherap* or prevent*)).ab.
4 (pharmacy or pharmacies or pharmacist*).af.
5 ((collaborat* or coordinat* or co-ordinat* or shared or integrat* or interdisciplinary or inter-disciplinary or stepped) adj3 (care or
healthcare or coach* or counsel* or working or service or model or effort* or intervention* or manage* or program* or treat* or therap*
or psychotherap* or prevent*)).ti,ab,id.
6 ((treatment or drug* or medicat* or pharmacotherap* or pharmaceutical* or therap* or psychotherap*) adj2 (adher* or comply or
complian* or nonadher* or noncomplian* or collabor* or commun* or educat* or advis* or advice or direct* or coach* or counsel* or
support* or proactive* or pro-active* or follow-up or coordinat* or co-ordinat* or shared or integrat* or stepped)).ti,ab,id.
7 (4 and (5 or 6))
8 or/1-3,7
9 (depress$ or dysthymi$ or mood or affective disorder* or affective symptom*).ti,ab,id.
10 ((mental* or psychiatr*) adj1 (ill* or disorder* or health or disease or diagnos*)).ti,id,hw.
11 depression.hw.
12 or/9-11
13 Psychopharmacology/ or Neuropsychopharmacology/
14 “3340”.cc.
15 exp Antidepressant Drugs/
16 Neurotransmitter Uptake Inhibitors/ or exp Serotonin Norepinepherine Reuptake Inhibitors/ or exp Serotonin Reuptake Inhibitors/
17 exp Monoamine Oxidase Inhibitors/
18 exp Tricyclic Antidepressant Drugs/
19 treatment compliance/ or client education/ or client participation/ or disease management/ or coaching/ or counseling/
20 (or/13-18) and 19
21 ((adheren* or compliance or nonadheren* or noncompliance or collabor* or communic* or educat* or advis* or advice or direct* or
counsel* or support* or proactive* or pro-active* or follow-up) adj3 (antidepress* or anti depress* or MAOI* or monoamine oxidase
inhibit* or ((serotonin or norepinephrine or noradrenaline or nor epinephrine or nor adrenaline or neurotransmitt* or dopamine*)
adj3 (uptake or reuptake or re-uptake)) or noradrenerg* or antiadrenergic or anti adrenergic or SSRI* or SNRI* or TCA* or psy-
chotropic*)).ti,ab,id.
22 20 or 21
23 clinical trials.sh.
24 (randomi#ed or randomi#ation or randomi#ing).ti,ab,id.
25 (RCT or at random or (random* adj3 (administ* or allocat* or assign* or class* or control* or determine* or divide* or division or
distribut* or expose* or fashion or number* or place* or recruit* or split or subsitut* or treat*))).ti,ab,id.
26 (control* and (trial or study or group) and (placebo or waitlist* or wait* list* or ((treatment or care) adj2 usual))).ti,ab,id,hw.
27 ((single or double or triple or treble) adj2 (blind* or mask* or dummy)).ti,ab,id.
28 trial.ti.
29 placebo.ti,ab,id,hw.
30 treatment outcome.md.
31 treatment effectiveness evaluation.sh.
32 mental health program evaluation.sh.
33 or/23-32
34 (8 and 12 and 33)
35 (8 and 22 and 33)
36 (34 or 35)
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***************************
Ovid Embase <1974 onwards>
Search Strategy:
--------------------------------------------------------------------------------
Intervention/Setting
[Pharmacist/pharmacy services-1]
1 PHARMACY/ or PHARMACY TECHNICIAN/
2 PHARMACIST/
3 PHARMACIST ATTITUDE/
4 (pharmacy or pharmacies or pharmacist*).ti,kw,hw.
5 ((pharmacy or pharmacies or pharmacist*) adj3 (advis* or advice or care or healthcare or coach* or commun* or counsel* or
intervention* or model* or program* or service* or support* or treat* or therap* or psychotherap* or prevent*)).ab.
[Pharmacist/pharmacy services-2]
6 (pharmacy or pharmacies or pharmacist*).af.
7 ((collaborat* or coordinat* or co-ordinat* or shared or integrat* or interdisciplinary or inter-disciplinary or stepped) adj3 (care or
healthcare or coach* or counsel* or working or service or model or effort* or intervention* or manage* or program* or treat* or therap*
or psychotherap* or prevent*)).ti,ab,kw.
8 ((treatment or drug* or medicat* or pharmacotherap* or pharmaceutical* or therap* or psychotherap*) adj2 (adher* or comply or
complian* or nonadher* or noncomplian* or collabor$ or commun* or educat* or advis* or advice or direct* or coach* or counsel* or
support* or proactive* or pro-active* or follow-up or collaborat* or coordinat* or co-ordinat* or shared or integrat* or stepped)).ti,ab,kw.
9 (6 and (7 or 8))
10 or/1-5,9
Population-1
11 (depress* or dysthymi* or mood or affective disorder* or affective symptom*).ti,ab,kw.
12 ((mental* or psychiatr*) adj1 (ill* or disorder* or health or disease or diagnos* or condition*)).ti,kw,hw.
13 exp DEPRESSION/
14 or/11-13
Population-2
15 exp ANTIDEPRESSIVE AGENT/
16 exp NEUROTRANSMITTER UPTAKE INHIBITORS/
17 exp MONOAMINE OXIDASE INHIBITORS/
18 exp TETRACYCLIC ANTIDEPRESSANT AGENT/ or exp TRICYCLIC ANTIDEPRESSANTAGENT/ or exp SEROTONIN
UPTAKE INHIBITOR/
19 PATIENT COMPLIANCE/ or MEDICATION COMPLIANCE/ or MEDICATION THERAPY MANAGEMENT/ or PA-
TIENT EDUCATION/ or COUNSELING/ or *PHARMACEUTICAL CARE/
20 (or/15-18) and 19
21 ((adheren* or compliance or nonadheren* or noncompliance or collabor$ or communic* or educat* or advis* or advice or direct* or
counsel* or support* or proactive* or pro-active* or follow-up) adj3 (antidepress* or anti depress* or MAOI* or monoamine oxidase
inhibit*)).ti,ab.
22 ((adheren* or compliance or nonadheren* or noncompliance or collabor$ or communic* or educat* or advis* or advice or direct* or
counsel* or support* or proactive* or pro-active* or follow-up) adj3 ((serotonin or norepinephrine or noradrenaline or nor epinephrine
or nor adrenaline or neurotransmitt* or dopamine*) adj3 (uptake or reuptake or re-uptake))).ti,ab.
23 ((adheren* or compliance or nonadheren* or noncompliance or collabor$ or communic* or educat* or advis* or advice or direct*
or counsel* or support* or proactive* or pro-active* or follow-up) adj3 (noradrenerg* or antiadrenergic or anti adrenergic or SSRI* or
SNRI* or TCA* or psychotropic* or psychoactive*)).ti,ab.
24 (20 or 21 or 22 or 23)
[RCT Filter]
25 randomized controlled trial/
26 randomization.de.
27 controlled clinical trial/ and (Disease Management or Drug Therapy or Prevention or Rehabilitation or Therapy).fs.
28 *clinical trial/
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29 placebo.de.
30 placebo.ti,ab.
31 trial.ti.
32 (randomi#ed or randomi#ation or randomi#ing).ti,ab,kw.
33 (RCT or “at random” or (random* adj3 (administ* or allocat* or assign* or class* or control* or determine* or divide* or division
or distribut* or expose* or fashion or number* or place* or recruit* or split or subsitut* or treat*))).ti,ab,kw.
34 ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$ or dummy)).mp.
35 (control* and (trial or study or group) and (placebo or waitlist* or wait* list* or ((treatment or care) adj2 usual))).ti,ab,kw,hw.
36 or/25-35
37 ((animal or nonhuman) not (human and (animal or nonhuman))).de.
38 (36 not 37)
39 (10 and 14 and 38) or (10 and 24 and 38)
***************************
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